This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
coronavirus: Archive
The Stock-Picking Puzzle: Putting The Pieces Together
by Bryan Hayes
The Stock-Picking Puzzle: Putting The Pieces Together
coronavirus dental dividend-investing dividends earnings hospitals investing large-cap medical medical-devices oncology-screening pharmaceuticals smart-health staffing vaccines
Bull of the Day: Pfizer Inc. (PFE)
by Bryan Hayes
With a dividend yield of 3% and a top Zacks VGM score of 'A', it's not hard to see why PFE is a top stock pick.
biotechnology biotechs cancer cell-therapy coronavirus dividend-investing dividends earnings genetics hospitals immuno-therapy investing large-cap medical oncology-screening pharmaceuticals vaccines
Fed Chair Powell's Wait & See Monetary Approach Is Bullish For Stocks
by Daniel Laboe
The Federal Reserve demonstrated an intentional lack of clarity in its post-meeting statements with significant emphasis on the flexibility
coronavirus earnings finance tech-stocks
Bear of the Day: Huazhu Group (HTHT)
by Bryan Hayes
A history of earnings misses and falling future estimates will continue to foster this stock's downtrend.
consumer-discretionary coronavirus earnings investing travel-leisure
The Power of Price Charts: Trust Your Eyes, Not Your Ears
by Bryan Hayes
The Power of Price Charts: Trust Your Eyes, Not Your Ears
artificial-intelligence automation coronavirus dividend-investing dividends earnings investing large-cap restaurants retail
How to Select Stocks During Volatile Market Periods
by Bryan Hayes
How to Select Stocks During Volatile Market Periods
biotechnology biotechs cancer cell-therapy coronavirus earnings investing large-cap medical pharmaceuticals smart-health
Follow The Leader: 3 Biopharma Stocks Displaying Relative Strength
by Bryan Hayes
3 Biopharma Stocks Displaying Relative Strength Heading Into 2022
biotechnology biotechs cancer cell-therapy coronavirus earnings gene-therapy genetics hospitals immuno-therapy investing medical oncology-screening pharmaceuticals smart-health vaccines
How To Play A Weakening US Dollar (Part 1)
by Daniel Laboe
The US dollar has been ripping higher since the Delta-variant showed up this summer, but its relative buoyancy looks to be at risk as we head into 2022
bitcoin consumer-discretionary coronavirus cryptocurrency finance multi-sector-conglomerates oil-energy
The Death Rate Soared Last Year - But Not Why You Might Think
by Bryan Hayes
3 Funeral Services Stocks Hitting All-Time Highs
cancer consumer-staples coronavirus earnings industrial-products investing medical
Cybersecurity, Inflation De-anchoring, COVID's Legacy
by John Blank
3 big risks in 2022 we must all think harder about.
coronavirus economy